Literature DB >> 26669768

Surgical Outcomes after Pulmonary Resection for Non-Small Cell Lung Cancer with Localized Pleural Seeding First Detected during Surgery.

Jae Kwang Yun1, Mi-Ae Kim2, Chang Min Choi2, Se Hoon Choi1, Yong-Hee Kim1, Dong Kwan Kim1, Seung-Il Park1, Hyeong Ryul Kim1.   

Abstract

OBJECTIVES: Curative resection is not indicated for non-small cell lung cancer (NSCLC) with pleural seeding, which is classified as stage IV (M1a) disease. However, some patients with a presumably resectable main tumor are diagnosed with localized pleural seeding during surgery.
METHODS: A retrospective analysis was performed of 3,975 patients who underwent surgery for NSCLC from 2000 to 2011. Among these cases, 78 (2.0%) patients had unexpected pleural seeding detected during surgery. Exploration with pleural biopsy was performed in 42 of these patients (exploration-only group) and pulmonary resection, including for the main tumor, was performed in 36 cases (resection group; sublobar resection in 12, lobectomy in 21, and pneumonectomy in 3 patients). Survival and cancer progression rates were estimated using the Kaplan-Meier method. Cox proportional hazard regression was used to evaluate prognostic factors associated with survival.
RESULTS: Adenocarcinoma was the predominant histological type in both the exploration and resection groups (88.1 and 86.1%, respectively). Epidermal growth factor receptor expression was detected in 22 (52.4%) patients of the exploration group and 21 (58.3%) patients of the resection group. Baseline characteristics including age, sex, comorbidity, pulmonary function, and clinical T/N status were not significantly different between the two groups. There were no postoperative deaths in either group but postoperative complications occurred in two (4.8%) patients of the exploration group and three (8.3%) patients of the resection group. The overall 3- and 5-year survival rates in the exploration group were 41.1 and 15.2%, respectively, with a median survival time (MST) of 33 months, whereas they were 66.7 and 42.7%, respectively, in the resection group, with a 52-month MST (p = 0.012). Local and regional progression-free rates were significantly different (p < 0.001 and p = 0.029, respectively) between groups, whereas no difference was seen in the distant metastasis rates (p = 0.957). In multivariate survival analysis, surgical resection was the only significant prognostic factor (p = 0.01).
CONCLUSIONS: Pulmonary resection including the main tumor, regardless of resection extent, may increase long-term survival for NSCLC patients with localized pleural seeding first detected during surgery, without a significant increase in hospital mortality or morbidity. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2015        PMID: 26669768     DOI: 10.1055/s-0035-1564928

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  11 in total

1.  Should primary tumor be resected for non-small cell lung cancer with malignant pleural disease unexpectedly found during operation?-a systemic review and meta-analysis.

Authors:  Yuyang Xu; Nan Chen; Zihuai Wang; Yingyi Zhang; Jiandong Mei; Chengwu Liu; Lunxu Liu
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

2.  Predictive factors related to pleural dissemination in non-small cell lung cancer.

Authors:  Nozomu Motono; Shun Iwai; Iijima Yoshihito; Katsuo Usuda; Sohsuke Yamada; Hidetaka Uramoto
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

3.  Primary tumor resection of non-small cell lung cancer patients with ipsilateral pleural dissemination (M1a) in the era of targeted therapy.

Authors:  Hao Li; Taorui Liu; Zewen Sun; Fan Yang
Journal:  Thorac Cancer       Date:  2020-09-18       Impact factor: 3.500

4.  Meta-analysis of P53 expression and sensitivity to platinum-based chemotherapy in patients with non-small cell lung cancer.

Authors:  Sheng Lin; Xiaoqin Li; Ming Lin; WenXiang Yue
Journal:  Medicine (Baltimore)       Date:  2021-02-05       Impact factor: 1.817

5.  Surgical choice of non-small cell lung cancer with unexpected pleural dissemination intraoperatively.

Authors:  Junjie Hu; Yan Chen; Xinsheng Zhu; Qiang Ma; Jing Zhang; Gening Jiang; Peng Zhang
Journal:  BMC Cancer       Date:  2021-04-22       Impact factor: 4.430

6.  Surgical Resection of Primary Tumors Provides Survival Benefits for Lung Cancer Patients With Unexpected Pleural Dissemination.

Authors:  Liwen Fan; Haitang Yang; Ke Han; Yang Zhao; Wen Gao; Ralph A Schmid; Feng Yao; Heng Zhao
Journal:  Front Surg       Date:  2021-06-23

Review 7.  New horizons in non-small-cell lung cancer patients with ipsilateral pleural dissemination (M1a): review of the literature.

Authors:  Hao Li; Taorui Liu; Zewen Sun; Zhenfan Wang; Xianping Liu; Fan Yang
Journal:  Ann Transl Med       Date:  2021-06

Review 8.  Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer.

Authors:  Mario Orozco-Morales; Giovanny Soca-Chafre; Pedro Barrios-Bernal; Norma Hernández-Pedro; Oscar Arrieta
Journal:  Mediators Inflamm       Date:  2016-01-28       Impact factor: 4.711

9.  Diffusion-weighted imaging diagnostic algorithm in patients with suspected pleural malignancy.

Authors:  Wenrui Jiang; Zhiping Han; Xing Tang; Hong Yin; Jian Zhang
Journal:  Eur Radiol       Date:  2021-05-28       Impact factor: 5.315

10.  Development and External Validation of a Nomogram for Predicting Cancer-Specific Survival of Non-Small Cell Lung Cancer Patients With Ipsilateral Pleural Dissemination.

Authors:  Zhenfan Wang; Hao Li; Taorui Liu; Zewen Sun; Fan Yang; Guanchao Jiang
Journal:  Front Oncol       Date:  2021-07-19       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.